Oramed Pharmaceuticals Inc. (ORMP) stock
Close on Nov 11, 2026Market cap $171.80MP/E 1.0Yield 6.05%
Oramed Pharmaceuticals Inc. reported revenue of $2.00M for fiscal 2025. Free cash flow was -$5.22M. At the latest close the market valued the company at $171.80M, 1.0 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $171.80M
- P/E ratio
- 1.0
- Price to sales
- –
- Price to book
- –
- Dividend yield
- 6.05%
- Free cash flow yield
- -3.04%
Fundamentals
- Revenue
- $2.00M
- Net income
- $174.87M
- EPS, diluted
- $4.13
- Free cash flow
- -$5.22M
- Diluted shares
- 43M
Trading
- Previous close
- $3.97
- Open
- $3.99
- Day's range
- $3.99 – $4.14
- Volume
- 105,529
- Average volume (20 days)
- 119,392
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 1.44
- 52-week range
- $2.23 – $5.47
- RSI (14 days)
- 48.6
- Volatility (1 year)
- 53.3%
- Relative volume
- 0.60×
- WACC
- 12.1%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ORMP | S&P 500 | Difference | ORMP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -4.6% | -2.4% | −2.2 pts | ||
| 3 months | -2.8% | -1.2% | −1.7 pts | ||
| Year to date | +55.4% | +12.3% | +43.2 pts | ||
| 1 year | +83.1% | +12.4% | +70.6 pts | ||
| 3 years | +130.7% | +78.8% | +51.9 pts | +32.1% | +21.4% |
| 5 years | -84.1% | +75.2% | −159.3 pts | -30.8% | +11.9% |
| 10 years | -29.3% | +311.1% | −340.4 pts | -3.4% | +15.2% |
Fifteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Oramed Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- Results
- Results
- Update
- Update
About Oramed Pharmaceuticals
Pharmaceutical Preparations
Oramed Pharmaceuticals Inc. is a pharmaceutical company that researches and develops oral delivery solutions for therapeutic proteins. Its proprietary Protein Oral Delivery technology enables oral formulations designed to protect active proteins, such as insulin, from gastrointestinal degradation and allow safe oral absorption without biological or chemical modification. In addition to internal development activities, the company allocates capital to strategic investments, royalty arrangements, and partnerships across healthcare, biotechnology, and life sciences businesses.
Company profile, executives and historyOramed Pharmaceuticals stock: common questions
What is Oramed Pharmaceuticals's stock price?
ORMP closed at $4.13 on Nov 11, 2026, up 4.03% on the day. Over the past 52 weeks it traded between $2.23 and $5.47.
What is Oramed Pharmaceuticals's market cap?
Oramed Pharmaceuticals was worth $171.80M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ORMP's P/E ratio?
ORMP trades at 1.0 times earnings, based on diluted earnings per share of $4.13 over the twelve months to Jun 30, 2026.
How much revenue does Oramed Pharmaceuticals make?
Oramed Pharmaceuticals reported revenue of $2.00M for fiscal 2025.
Does Oramed Pharmaceuticals pay a dividend?
Yes. Oramed Pharmaceuticals paid $0.25 per share over the last twelve months, a yield of 6.05% at the latest price.
How has ORMP stock performed over the past year?
Including dividends, ORMP returned +83.1% over the past year, against +12.4% for the S&P 500.
How many ORMP shares are sold short?
1M shares were sold short at the latest FINRA report, 4.25% of the float, or 11.3 days of average trading volume.
Who are Oramed Pharmaceuticals's competitors?
Companies most similar to Oramed Pharmaceuticals by business, industry and size include MCRB, RANI, LPCN, RFL, TRAW.
See a number that looks wrong?